JAYPIRCA PIRTOBRUTINIB 吡托布替尼片

Jaypirca (pirtobrutinib) Pirobutinib Tablet Indications
Jaypirca is a kinase inhibitor used to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two systemic therapies, including a BTK inhibitor.
Jaypirca (pirtobrutinib) Pirobutinib Tablet Specifications
Tablets: 50mg, 100mg
Jaypirca (pirtobrutinib) Pirobutinib Tablet Usage and Dosage
Recommended dose: 200 mg once daily, with or without food, until disease progression or unacceptable toxicity occurs.
Jaypirca (pirtobrutinib) Pirobutinib Tablet Contraindications
None.
Jaypirca (pirtobrutinib) Pirobutinib Tablet Mechanism of Action
Pirtobrutinib is a small molecule, non-covalent BTK inhibitor. BTK is a signaling protein in the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling leads to activation of pathways required for B cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild-type BTK and BTK carrying the C481 mutation, resulting in inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated CD69 expression on B cells and suppressed malignant B cell proliferation. Pirtobrutinib demonstrated dose-dependent antitumor activity in BTK wild-type and BTK C481S mutant mouse xenograft models.

Jaypirca (pirtobrutinib) Pirtobrutinib Tablets Storage

Store JAYPIRCA tablets at room temperature 20°C to 25°C (68°F to 77°F); excursions between 15°C and 30°C (59°F and 86°F) are permitted ([see USP Controlled Room Temperature]).

Jaypirca (pirtobrutinib) Pirtobrutinib Tablets Precautions

• Infection: Monitor for signs and symptoms of infection, evaluate and treat promptly.
• Bleeding: Monitor for bleeding and manage appropriately.
• Cytopenia: Monitor complete blood counts during treatment.
• Atrial fibrillation and atrial fibrillation: Monitor for arrhythmic symptoms and manage appropriately.
• Second primary malignancies: Other malignancies have developed, including skin cancer and other cancers. Monitor and advise patients to use sunscreen.
• Embryo-fetal toxicity: May cause fetal harm. Advise women of the potential risk to the fetus and take effective contraceptive measures.

Jaypirca (pirtobrutinib) Pirtobrutinib Tablets Adverse Reactions
The most common adverse reactions (≥15%) are fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.